Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.44)
# 928
Out of 5,072 analysts
106
Total ratings
47.62%
Success rate
5.66%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $5.30 | +107.55% | 2 | Oct 30, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $4.22 | +42.18% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $3.34 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $488.43 | +7.49% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $55.52 | +62.10% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $432.17 | +11.07% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $49.25 | +11.68% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $127.51 | -37.26% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $9.63 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $784.61 | +29.36% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $344.57 | +17.54% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $445.12 | -50.58% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $16.37 | -38.91% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.38 | +20.82% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $53.30 | +35.08% | 1 | Apr 13, 2023 |
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.30
Upside: +107.55%
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $4.22
Upside: +42.18%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.34
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $488.43
Upside: +7.49%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $55.52
Upside: +62.10%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $432.17
Upside: +11.07%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $49.25
Upside: +11.68%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $127.51
Upside: -37.26%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $9.63
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $784.61
Upside: +29.36%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $344.57
Upside: +17.54%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $445.12
Upside: -50.58%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $16.37
Upside: -38.91%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.38
Upside: +20.82%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $53.30
Upside: +35.08%